These practice guidelines provide evidence-based recommendations on the management of neuromuscular monitoring and antagonism of neuromuscular blocking agents during and after general anesthesia. The guidance focuses primarily on the type and site of monitoring and the process of antagonizing neuromuscular blockade to reduce residual neuromuscular blockade.
|Original language||English (US)|
|Number of pages||29|
|State||Published - Jan 1 2023|
Bibliographical noteFunding Information:
Dr. Lien serves on the Scientific Advisory Board of Senzime. Dr. Eriksson received lecture and medical advisory fees from Senzime AB (Sweden) and Merck (Sweden). Dr. Domino received a research grant from Edwards Life Science Corporation. Dr. S. A. Grant has noted the following financial relationships: SPR Therapeutics (Cleveland, Ohio); Oxford University Press USA (New York, New York), royalties from a textbook; BBraun USA (Bethlehem, Pennsylvania) past relationship consulting. None of these have any relation to the article’s content. The other authors declare no competing interests.
© 2023 Lippincott Williams and Wilkins. All rights reserved.
PubMed: MeSH publication types
- Journal Article
- Research Support, Non-U.S. Gov't